| Abbott (23) |  |
| Amgen (10) | |
| Astra-merck (6) | |
| Bayer (41) | |
| Boehringer-ingelheim (1) | |
| Bristol-myers-squibb (5) | |
| Dupont-merck (14) | |
| Eli lilly (5) | |
| Genentech (5) | |
| Genzyme (5) | |
| Glaxosmithkline (26) | |
| Hoechst-marion-roussel (4) | |
| Pasteur-merieux (8) | |
| Pfizer (22) | |
| Pharmaceutical industry (36) | |
| Pharmaceutical laboratory (1) | |
| Pharmacyclics (1) | |
| Roche pharmaceuticals (16) | |
| Sanofi-aventis (6) | |
| Stallergenes (1) | |
| Whitehall laboratories (3) | |
Business Genzyme fined: On 24 may, the US Food and Drug Administration (FDA) fined Genzyme US$175 million for poor oversight at one of its manufacturing plants.
Efforts by the biotechnology company, based in Cambridge, Massachusetts, to clean the plant will cause shortages of three drugs,
on 25 may, after years of struggle, Genzyme won FDA approval to market Lumizyme (alglucosidase-Ã Â) for patients with late-onset Pompe disease, a muscle-weakening illness.
Earlier this year, Genzyme, a drug company based in Cambridge, Massachusetts, that makes alemtuzumab and a range of other therapies, was acquired by Paris-based drug-maker Sanofi.
The value of the deal for Genzyme's shareholders is contingent on the success of alemtuzumab in treating MS;
< Back - Next >
Overtext Web Module V3.0 Alpha
Copyright Semantic-Knowledge, 1994-2011